Hyperparathyroidism and Mobility decreased

Summary:

Mobility decreased is found among people with Hyperparathyroidism, especially for people who are female, 60+ old.

The study analyzes which people have Mobility decreased with Hyperparathyroidism. It is created by eHealthMe based on reports of 17 people who have Hyperparathyroidism from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Hyperparathyroidism?

Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium) is found to be associated with 453 drugs and 445 conditions by eHealthMe. Check the latest studies of Hyperparathyroidism.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,774 drugs and 1,635 conditions by eHealthMe. Check the latest studies of Mobility decreased.

On Jul, 26, 2026

17 people who have Hyperparathyroidism and Mobility Decreased are studied.

Would you have Mobility decreased when you have Hyperparathyroidism?

Gender of people who have Hyperparathyroidism and experienced Mobility Decreased *:

female: 75 %
male: 25 %

Age of people who have Hyperparathyroidism and experienced Mobility Decreased *:

Common co-existing conditions for these people *:

Pain: 7 people, 41.18%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 4 people, 23.53%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 23.53%
Breast Cancer: 4 people, 23.53%
Bleeding Disorders: 4 people, 23.53%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 23.53%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 4 people, 23.53%
Hypersensitivity: 4 people, 23.53%
Hypotension (abnormally low blood pressure): 4 people, 23.53%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 4 people, 23.53%

Common drugs taken by these people *:

Sensipar: 6 people, 35.29%
Zyrtec: 5 people, 29.41%
Prilosec: 5 people, 29.41%
Zemplar: 5 people, 29.41%
Vicodin: 5 people, 29.41%
Midodrine Hydrochloride: 4 people, 23.53%
Coreg: 4 people, 23.53%
Plavix: 4 people, 23.53%
Phoslo: 4 people, 23.53%
Coumadin: 4 people, 23.53%

Common symptoms for these people *:

Weakness: 10 people, 58.82%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 6 people, 35.29%
Infection: 5 people, 29.41%
Joint Pain: 5 people, 29.41%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 5 people, 29.41%
Pain: 5 people, 29.41%
Pain In Extremity: 5 people, 29.41%
Joint Range Of Motion Decreased (disease of joint movement): 4 people, 23.53%
Rash Papular (redness with papule): 4 people, 23.53%
Fall: 4 people, 23.53%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition

Related studies:

Treatments, associated drugs and conditions:

Hyperparathyroidism (5,278 reports)
Mobility decreased (83,538 reports)

All the drugs that are associated with Mobility decreased:

Mobility decreased (1,774 drugs)

All the conditions that are associated with Mobility decreased:

Mobility decreased (1,635 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Mobility decreased and Hyperparathyroidism, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.